MAINZ BIOMED NV (MYNZ)
NL0015000LC2 - Common Stock
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update...
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-Baden
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert ...
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025...
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador...
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of AI for the Expansion and Optimization of Biomarker Selection for PancAlert...
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning!
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test...
Mainz Biomed Provides Half Year 2024 Corporate Update
Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study
Mainz Biomed Provides Half Year 2024 Corporate Update
Mainz Biomed Provides Half Year 2024 Corporate Update - Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study...
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024...
Mainz Biomed Reports Results of 2024 Annual General Meeting
Mainz Biomed Reports Results of 2024 Annual General Meeting
Mainz Biomed Reports Results of 2024 Annual General Meeting...